Anaplastic Lymphoma Kinase Non-Small-Cell Lung Cancer - Epidemiology Forecast - 2036

ALK NSCLC Insights and Trends

• According to DelveInsight's analysis, the total incident cases of ALK NSCLC were approximately 10,100 in the United States in 2025.
• ALK-positive NSCLC is a genetically defined subset of lung cancer characterized by rearrangements in the ALK gene that drive uncontrolled tumor growth. It is most commonly seen in younger patients.
• Current clinical guidelines recommend that all patients with advanced non-squamous NSCLC (and selected squamous cases) undergo broad molecular profiling at diagnosis or progression, including mandatory ALK testing.
• A key challenge in ALK-positive NSCLC is disease relapse, particularly in the brain, as CNS metastases are common and can occur even when systemic disease is controlled. While newer ALK inhibitors offer better CNS penetration, long-term disease control remains limited, and resistance continues to emerge over time.

Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer (ALK NSCLC) Epidemiology Forecast in the US

• 2025 Incident of ALK NSCLC: ~25,500
• 2036 Projected ALK NSCLC Incident Cases: ~27,600
• ALK NSCLC Growth Rate (2026-2036): ~0.5% CAGR

DelveInsight's 'ALK NSCLC - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the gastroparesis, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer (ALK NSCLC) Understanding and Diagnosis Algorithm

ALK NSCLC Overview

ALK-positive non-small cell lung cancer (ALK NSCLC) is a distinct molecular subtype of lung cancer characterized by rearrangements in the anaplastic lymphoma kinase (ALK) gene, most commonly the EML4-ALK fusion. It is more frequently observed in younger patients, non-smokers, or light smokers with adenocarcinoma histology. This subtype is clinically significant because it is highly responsive to targeted therapies, which have transformed prognosis compared to conventional chemotherapy. The disease often shows a tendency to spready early to the central nervous system (CNS), making effective brain-penetrant therapies especially important.

ALK NSCLC Diagnosis

The diagnosis of ALK NSCLC relies on molecular testing to identify ALK gene rearrangements. Patients with advanced non-squamous NSCLC are routinely tested using techniques such as immunohistochemistry, fluorescence in situ hybridization, or next-generation sequencing (NGS), with NGS increasingly preferred due to its ability to detect multiple genomic alterations simultaneously. Accurate and early identification of ALK status is critical, as it directly guides treatment decisions. Imaging studies, including MRI of the brain, are also commonly performed given the high incidence of CNS metastases in this patient population.

Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer (ALK NSCLC) Epidemiology

Key Findings from ALK NSCLC Epidemiological Analysis and Forecast

• Among the 7MM, the US accounted for the highest number of incident cases of NSCLC with ~10,000 cases in 2025.
• NSCLC shows a higher incidence in males, accounting for 56% of cases, compared to 44% in females.
• Among the age groups, the highest age-specific cases accounted for 65+ years in 2025 with more than 65% of the total cases.
• In the US, out of all the stages, the highest stage-specific cases accounted for stage IV, followed by stage I in 2025. While the least stage-specific cases were observed in stage IIIB.
• Among EU4 and the UK, Germany accounted for the highest incident cases of ALK NSCLC, followed by Uk, and the least cases were accounted for by Spain in the year 2025.

Scope of the Report:

• The report covers a segment of a descriptive overview of gastroparesis, explaining their causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

ALK NSCLC Patient Population Forecast

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• 11-year Forecast
• Patient Burden Trends (by geography)

FAQs:

• What are the disease risks, burdens, and unmet needs of gastroparesis? What will be the growth opportunities across the 7MM concerning the patient population with gastroparesis?
• What is the historical and forecasted gastroparesis patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.